Menu
Search
|

Menu

Close
X

Alpine Immune Sciences Inc ALPN.OQ (NASDAQ Stock Exchange Global Market)

5.06 USD
-0.25 (-4.71%)
As of Oct 19
chart
Previous Close 5.31
Open 5.29
Volume 745
3m Avg Volume 4,845
Today’s High 5.29
Today’s Low 5.06
52 Week High 11.85
52 Week Low 4.93
Shares Outstanding (mil) 13.88
Market Capitalization (mil) 168.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
3
FY15
0
EPS (USD)
FY18
-0.954
FY17
-8.395
FY16
33.729
FY15
-6.077
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.65
Price to Sales (TTM)
vs sector
--
5.82
Price to Book (MRQ)
vs sector
4.14
4.89
Price to Cash Flow (TTM)
vs sector
--
22.93
Total Debt to Equity (MRQ)
vs sector
0.00
17.17
LT Debt to Equity (MRQ)
vs sector
0.00
12.75
Return on Investment (TTM)
vs sector
-48.40
14.28
Return on Equity (TTM)
vs sector
-48.40
16.00

EXECUTIVE LEADERSHIP

Mitchell Gold
Executive Chairman of the Board, Chief Executive Officer, Assistant Secretary, Since 2017
Salary: --
Bonus: --
Mark Litton
President, Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Paul Rickey
Chief Financial Officer, Senior Vice President, Secretary, Since 2017
Salary: --
Bonus: --
Stanford Peng
Executive Vice President - Research and Development, Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Sherif Gabriel
Vice President – Research and Discovery, Since 2012
Salary: $295,687.00
Bonus: $50,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

201 Elliott Ave W Ste 230
SEATTLE   WA   98119-4230

Phone: +1206.7884545

Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.

SPONSORED STORIES